Key result
Levetiracetam treatment significantly increased heart rate variability at 3 months compared to baseline (p < 0.05), indicating no negative effect on potential cardiac arrhythmia risk.
Why the study?
This study investigated the effects of levetiracetam treatment on cardiac rhythm and heart rate variability in pediatric patients with non-lesional epilepsy.
Does levetiracetam treatment affect heart rate variability and cardiac rhythm in pediatric epilepsy patients?
Observational (n=60)
No
Does levetiracetam treatment affect heart rate variability and cardiac rhythm in pediatric epilepsy patients?
p-value: p=<0.05
Levetiracetam treatment in pediatric epilepsy patients improves sympathovagal balance and does not negatively impact heart rate variability or increase arrhythmia risk.
LEV monotherapy was associated with improved HRV in children with epilepsy; hypothesis-generating for autonomic safety, requires randomized confirmation before practice change.
BACKGROUND: This study investigated the effects of levetiracetam (LEV) treatment on cardiac rhythm and heart rate variability. METHODS: The study included two groups of patients diagnosed with non-lesional epilepsy who had not yet been treated and who presented to the outpatient pediatric neurology clinic at Van Training and Research Hospital, Van, Turkey, between 2019 and 2020. The heart rate variability (HRV) of 47 patients in the first group, before and at the 3rd month of treatment, and intravenous (IV) LEV loading in 13 patients in the second group was evaluated by Holter electrocardiography (ECG). RESULTS: It was determined that the values of triangular index, standard deviation of the RR intervals over a 24-hour period (SDNN), standard deviation of all 5-minute mean RR intervals (SDANN), mean of standard deviations of all normal RR intervals (SDNNI), the percentage of RR intervals with >50-millisecond variation (PNN50), and the square root of mean squared differences of successive RR intervals (RMSSD). HRV of 47 patients under LEV treatment significantly increased in the 3rd month of treatment compared to baseline (p < 0.05). No difference was found in HRV between the intravenous loading and the control group (p > 0.05). CONCLUSIONS: Our study suggests that the sympathovagal balance before treatment in the patient group is in favor of the sympathetic nervous system and that the sympathovagal imbalance improves after treatment. Our results show that LEV monotherapy and loading have no negative effect on HRV and potential cardiac arrhythmia risk in children with epilepsy.
No takes yet. Share an insight, caveat, or question.
Direk et al. (2023) conducted an observational in Pediatric non-lesional epilepsy (n=60). Levetiracetam vs. Baseline (pre-treatment) and control group was evaluated on Heart rate variability (HRV) (p=<0.05). Levetiracetam treatment significantly increased heart rate variability at 3 months compared to baseline (p < 0.05), indicating no negative effect on potential cardiac arrhythmia risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: